Business Wire

Thales Launches Europe’s First Certified Smartcard Ready for the Quantum Age

7.10.2025 09:00:00 EEST | Business Wire | Press release

Share

As quantum computing evolves, many of today’s cryptographic methods will no longer be secure, since quantum computers will be able to solve complex mathematical problems much faster than classical computers. A recent Gartner® report* says “By 2029, advances in quantum computing will make conventional asymmetric cryptography unsafe to use.” Thales has spent years investing in post-quantum cryptography to ensure critical systems stay safe in the future.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251006066043/en/

© Sanna Liimatainen - Thales

By becoming the first company worldwide to receive high-level Common Criteria1 certification for a quantum-resistant smartcard, Thales will help government services protect sensitive data—such as those on ID cards, health cards, and driver’s licenses—and ensure that citizens’ identities are secure against emerging quantum threats.

The innovative smartcard (MultiApp 5.2 Premium PQC’), developed by Thales and certified by the French Cybersecurity Agency (Agence nationale de la sécurité des systèmes d’information – ANSSI), uses advanced digital signature designed to resist attacks, even from powerful quantum machines. It’s the first of its kind to be certified at such a high security level (EAL 6+2) under the Common Criteria framework. The certified product also features new Digital Signature Algorithms3 standardised by the American NIST - National Institute of Standards and Technology. These specific signature algorithms are powerful cryptographic tools used to verify that data or a digital message really comes from the right sender and has not been altered.

From an end-user perspective, nothing changes: citizens will continue to use their cards as usual. What’s revolutionary is what’s inside. The card uses a new generation cryptographic signature designed to withstand the immense computing power of tomorrow’s quantum computers. This ensures that sensitive personal data remains protected not just today—but well into the future.

"This first certification for a solution incorporating post-quantum cryptography reflects ANSSI’s commitment to supporting innovation, while upholding the highest cybersecurity standards. The joint work of Thales, CEA-Leti ITSecurity Evaluation Facility, and ANSSI is a strong signal that Europe is ready to lead the way in post-quantum security, enabling organisations and governments to deploy solutions that anticipate future risks, rather than waiting for quantum computers to become mainstream."Franck Sadmi, Head ofNational Certification Center,French Cybersecurity Agency (ANSSI).

"This certification is a landmark moment not only for Thales but for the entire digital security ecosystem. It shows that future-proof cybersecurity is no longer a concept—it's a reality. By achieving the highest level of security for a quantum-resistant smartcard, Thales is paving the way for trust in tomorrow’s civil identities. We’re proud to lead this crucial transformation."Nathalie Gosset, VP Identity & Biometric Solutions at Thales.

1 An international standard confirming the product meets strict security requirements.

2 The Evaluation Assurance Level (EAL) is an international scale used to measure the robustness of IT security. It ranges from EAL1 (basic tested) up to EAL7 (the highest, formally verified level). An EAL6+ certification means the product has been tested and proven to provide very high security against sophisticated attacks, suitable for critical applications like government, finance, and defense.

3 FIPS 204 is a new U.S. government standard that defines a digital signature algorithm designed to remain secure even in the age of quantum computers. It is a foundation for digital integrity of things like secure transactions, ID documents, software updates, or electronic contracts. FIPS standards are published and approved by NIST (the U.S. National Institute of Standards and Technology) and are widely recommended and adopted across industries worldwide, especially in sectors like government, defense, finance, and digital technology.

* Gartner®, Postquantum Cryptography: The Time to Prepare Is Now!, Mark Horvath et al., 1 July 2024

The Gartner content described herein (the “Gartner Content”) represents research opinion or viewpoints published, as part of a syndicated subscription service, by Gartner, Inc. ("Gartner"), and is not a representation of fact. Gartner Content speaks as of its original publication date (and not as of the date of this PR), and the opinions expressed in the Gartner Content are subject to change without notice.

GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies for the Defence, Aerospace, and Cyber & Digital sectors. Its portfolio of innovative products and services addresses several major challenges: sovereignty, security, sustainability and inclusion.

The Group invests more than €4 billion per year in Research & Development in key areas, particularly for critical environments, such as Artificial Intelligence, cybersecurity, quantum and cloud technologies.

Thales has more than 83,000 employees in 68 countries. In 2024, the Group generated sales of €20.6 billion.

PLEASE VISIT
Thales Group
Download HD photos

View source version on businesswire.com: https://www.businesswire.com/news/home/20251006066043/en/

Contacts

PRESS CONTACT
Thales, Media Relations CYBER & DIGITAL
Vanessa Viala – vanessa.viala@thalesgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye